Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
The regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption of Stevanato Group's proprietary Alina® pen injector platform across Europe.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730802297/en/
The approved configurations include Alina® 30, developed for liraglutide-based therapies for diabetes, and Alina® 50, designed for liraglutide-based weight management applications. Both variants are part of Stevanato Group's broader Alina® variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies.
